Baxter International Inc (NYSE:BAX) Director John D. Forsyth sold 310 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $83.59, for a total transaction of $25,912.90. Following the transaction, the director now directly owns 34,279 shares of the company’s stock, valued at $2,865,381.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
BAX traded up $0.79 on Wednesday, reaching $81.30. The company’s stock had a trading volume of 22,657 shares, compared to its average volume of 2,686,703. The stock has a 50 day moving average of $83.94 and a two-hundred day moving average of $85.28. The company has a quick ratio of 2.31, a current ratio of 2.97 and a debt-to-equity ratio of 0.74. The company has a market capitalization of $42.11 billion, a price-to-earnings ratio of 25.76, a P/E/G ratio of 2.79 and a beta of 0.79. Baxter International Inc has a fifty-two week low of $69.10 and a fifty-two week high of $95.19.
Baxter International (NYSE:BAX) last announced its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $0.64 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.71 by ($0.07). The business had revenue of $2.72 billion during the quarter, compared to analyst estimates of $2.86 billion. Baxter International had a net margin of 8.10% and a return on equity of 20.75%. The business’s revenue for the quarter was down 4.3% compared to the same quarter last year. During the same period last year, the company earned $0.89 earnings per share. As a group, analysts anticipate that Baxter International Inc will post 3.05 earnings per share for the current fiscal year.
A number of analysts have commented on the stock. Credit Suisse Group reaffirmed a “buy” rating and set a $99.00 target price on shares of Baxter International in a report on Tuesday, August 11th. Morgan Stanley reduced their target price on shares of Baxter International from $95.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Friday, July 31st. Oppenheimer reaffirmed a “buy” rating on shares of Baxter International in a research note on Thursday, July 30th. Zacks Investment Research downgraded shares of Baxter International from a “hold” rating to a “sell” rating and set a $93.00 target price on the stock. in a research report on Tuesday, July 7th. Finally, Raymond James lowered their price target on shares of Baxter International from $97.00 to $95.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and thirteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $96.72.
A number of institutional investors and hedge funds have recently made changes to their positions in BAX. Two Sigma Advisers LP increased its position in shares of Baxter International by 146.3% in the second quarter. Two Sigma Advisers LP now owns 2,512,149 shares of the medical instruments supplier’s stock valued at $216,296,000 after buying an additional 1,492,100 shares in the last quarter. Schonfeld Strategic Advisors LLC boosted its stake in Baxter International by 235.9% in the 2nd quarter. Schonfeld Strategic Advisors LLC now owns 28,176 shares of the medical instruments supplier’s stock worth $2,426,000 after buying an additional 19,788 shares during the last quarter. Principal Financial Group Inc. boosted its stake in Baxter International by 4.5% in the 2nd quarter. Principal Financial Group Inc. now owns 748,929 shares of the medical instruments supplier’s stock worth $64,483,000 after buying an additional 32,555 shares during the last quarter. Garde Capital Inc. boosted its stake in Baxter International by 12.6% in the 2nd quarter. Garde Capital Inc. now owns 2,815 shares of the medical instruments supplier’s stock worth $242,000 after buying an additional 315 shares during the last quarter. Finally, Neuberger Berman Group LLC lifted its stake in shares of Baxter International by 5.8% in the 2nd quarter. Neuberger Berman Group LLC now owns 1,036,646 shares of the medical instruments supplier’s stock valued at $89,222,000 after purchasing an additional 57,156 shares in the last quarter. 84.23% of the stock is owned by hedge funds and other institutional investors.
About Baxter International
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Featured Article: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.